According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
Several other equities research analysts have also weighed in on the stock. Mizuho reaffirmed a “buy” rating and issued a $4.00 target price on shares of Selecta Biosciences in a report on Sunday. ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $6.00 target price on shares of Selecta Biosciences in a report on Friday, August 9th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. Selecta Biosciences currently has an average rating of “Hold” and a consensus price target of $7.88.
Selecta Biosciences (NASDAQ:SELB) last posted its earnings results on Thursday, August 8th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.07). The firm had revenue of $0.01 million for the quarter. On average, analysts predict that Selecta Biosciences will post -1.35 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in Selecta Biosciences during the 2nd quarter valued at about $31,000. Rhumbline Advisers lifted its position in Selecta Biosciences by 43.5% during the 1st quarter. Rhumbline Advisers now owns 34,158 shares of the company’s stock valued at $81,000 after purchasing an additional 10,356 shares during the period. Two Sigma Advisers LP lifted its position in Selecta Biosciences by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock valued at $146,000 after purchasing an additional 8,500 shares during the period. Deutsche Bank AG lifted its position in Selecta Biosciences by 251.6% during the 4th quarter. Deutsche Bank AG now owns 127,121 shares of the company’s stock valued at $337,000 after purchasing an additional 90,970 shares during the period. Finally, Geode Capital Management LLC lifted its position in Selecta Biosciences by 17.9% during the 4th quarter. Geode Capital Management LLC now owns 175,308 shares of the company’s stock valued at $466,000 after purchasing an additional 26,568 shares during the period. 49.43% of the stock is currently owned by institutional investors and hedge funds.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Read More: Holder of Record
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.